Pharmaceutical Business review

CardioDynamics Q1 net loss narrows

The company has reported net sales of $5.07 million for the first quarter of 2009 compared to $5.76 million for the same period of 2008.

Michael Perry, CEO of CardioDynamics, said: “We were encouraged by continued growth in the business excluding the large international opportunity that we recorded in the first quarter, 2008. We were particularly pleased with the increased growth in our sensor business which was up 12% during the quarter.

“In an effort to augment overall revenue growth, we launched a pilot sales program for a new partner product midway through the quarter with a small group of our sales team. We will evaluate the progress in the pilot program during the second quarter to decide whether to introduce the product to the entire sales force during the second half of 2009.”